Andrew L. Feldman, MD, a Damon Runyon Scientist

Loading...

Sign in or sign up now!
Alert icon
Upgrade to the latest Flash Player for improved playback performance. Upgrade now or more info.
64 views
Loading...
Alert icon
Sign in or sign up now!
Alert icon

Uploaded by on Sep 12, 2011

Andy's research focuses on defining the role of the transcription factor IRF4 in T-cell lymphomas (TCLs), aggressive cancers that are fatal in the majority of patients. He proposes that IRF4 represents a rational therapeutic target for TCLs and aims to develop new strategies to block IRF4 in lymphoma cells. Novel targeted therapies for TCL could greatly improve the outcome for patients with this disease.

Learn more at www.damonrunyon.org

  • likes, 0 dislikes

Link to this comment:

Share to:
see all

All Comments (0)

Sign In or Sign Up now to post a comment!
Loading...

Alert icon
0 / 00Unsaved Playlist Return to active list
    1. Your queue is empty. Add videos to your queue using this button:
      or sign in to load a different list.
    Loading...Loading...Saving...
    • Clear all videos from this list
    • Learn more